Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pasireotide
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-19 of 19 for your search:
Start Over
Placebo Controlled Trial of SOM230 for the Reduction of Post-Pancreatectomy Fistula, Leak, and Abscess
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09-039, NCT00994110
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230C2402, 2009-016722-13, EUDRACT 2009-016722-13, NCT01137682
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-031, NCI-2011-03216, NCT01468532
Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB00051599, WCI2031-11, NCT01469572
Study Evaluating SOM230 in Patients With Metastatic Carcinoid Tumors
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2202, NCT00088595
Monthly SOM230C for Recurrent or Progressive Meningioma
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-266, CSOM230CUS09T, NCT00859040
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230D2203, 2008-007348-32, NCT00958841
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16438, CSOM230DUS23T, NCT01253161
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230I2201, 2010-023183-40, NCT01374451
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LCCC 1032, NCT01488487
3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230DIC03, 2011-002872-17, NCT01563354
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230C2110, 2005-003348-75, NCT00446082
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-087, NCT00804336
Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230F2102, 2010-018895-26, NCT01263353
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230D2101, NCT01364415
SOM 230 and Gemcitabine in Advanced Pancreatic Cancer
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16456, CSOM230CUS16T, NCT01385956
Phase I Trial of Combination of FOLFIRI and SOM 230
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-16569, SOM230CUS17T, NCT01434069
Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001KDE47, NCT01590199
Start Over